A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Zalcitabine has been studied across 14 research domains including ⚡ Energy & Fatigue, 💊 Pain, 🔬 Oncology, 🫁 Liver & Detox, 🔥 Metabolic. The primary research focus is ⚡ Energy & Fatigue with 13% of studies addressing this area.
This evidence profile for Zalcitabine is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.